Patent · US Active

Sydnonimines-specific dopamine reuptake inhibitors and their use in treating dopamine related disorders

US9604945B2 · kind B2 · utility

0Cited by
8References
11Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 27, 2013
Grant dateMar 28, 2017
Priority date
Expiry dateMar 27, 2033

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P43/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Derivatives of Sydnonimine and its analogues, which bind selectively to dopamine transporter (DAT) proteins are useful for treating and delaying the progression of disorders and illnesses that are alleviated by inhibiting dopamine reuptake.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.